Results 71 to 80 of about 62,929 (228)

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez   +17 more
wiley   +1 more source

Chinese expert consensus on whole-process management of oxaliplatin-induced hypersensitivity reactions (2024 edition) [PDF]

open access: yesZhongguo aizheng zazhi
Oxaliplatin serves as a basic therapeutic agent for various malignant tumors. Oxaliplatin-induced hypersensitivity reactions are potentially life-threatening, and frequently lead to treatment discontinuation.
Cancer Assessment Society of China Anti-Cancer Association, Cancer Pain Society of Fujian Anti-Cancer Association
doaj   +3 more sources

Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles.

open access: yesPLoS ONE, 2015
The platinum-based anticancer drug oxaliplatin is important clinically in cancer treatment. However, the role of multidrug resistance-associated protein 2 (MRP2) in controlling oxaliplatin membrane transport, in vivo handling, toxicity and therapeutic ...
Khine Myint   +3 more
doaj   +1 more source

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

open access: yesAdvanced NanoBiomed Research, EarlyView.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

Mesoporous Silica Nanoparticles With Customized Drug Ratio/Loading for Effective Treatment of Gemcitabine‐Resistant Pancreatic Tumors

open access: yesAdvanced NanoBiomed Research, EarlyView.
Redox responsive mesoporous silica nanoparticles (MSNs) were engineered to deliver gemcitabine (Gem) and cisplatin (cisPt) at defined ratios to overcome chemoresistance in pancreatic ductal adenocarcinoma (PDAC). Optimized Gem MSNs and Gem cisPt MSNs enhanced cytotoxicity in murine and human Gem resistant models, with select formulations inducing ...
Tamanna Binte Huq   +5 more
wiley   +1 more source

Sensitization of capsaicin and icilin responses in oxaliplatin treated adult rat DRG neurons

open access: yesMolecular Pain, 2010
Background Oxaliplatin chemotherapy induced neuropathy is a dose related cumulative toxicity that manifests as tingling, numbness, and chronic pain, compromising the quality of life and leading to discontinued chemotherapy.
Anand Praveen, Otto William R, Anand Uma
doaj   +1 more source

Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Background Regulatory guidance in the United Kingdom advises DPYD genotyping prior to fluoropyrimidine‐based treatment. This economic evaluation estimated the costs and outcomes associated with DPYD screening prior to prescribing fluoropyrimidines for colorectal cancer in Wales and also considers additional variants to those included in ...
Catrin O. Plumpton   +8 more
wiley   +1 more source

Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells

open access: yesJournal of Experimental & Clinical Cancer Research, 2018
Background Oxaliplatin belongs to the platinum-based drug family and has shown promise in treating cancer by binding to DNA to induce cytotoxicity. However, individual patients show diverse therapeutic responses toward oxaliplatin due to yet-unknown ...
Huei-Yu Chen   +5 more
doaj   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

open access: yesBMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu   +5 more
wiley   +1 more source

Chemotherapeutic Potential of Fluorouracil‐Platinum (IV) Prodrugs Against Cisplatin‐Resistant Colorectal Cancer Cells

open access: yesChemistry – A European Journal, EarlyView.
ABSTRACT Fluorouracil‐platinum(IV) prodrugs represent a novel class of multimechanistic chemotherapeutics with enhanced anticancer potential. The prodrugs PtIVP‐5FUMeOBut and PtIV56‐5FUMeOBut were actualized by derivatising the clinical drug 5‐fluorouracil (5FU) and coordinating it to platinum(IV) complexes, leveraging the established cytotoxicity of ...
Maria George Elias   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy